15
First head-to-head comparison of CDK4/6 inhibitors in cell line and animal models of breast cancer reveals important differences, including one drug that exhibits unique, potentially advantageous therapeutic activity.
First head-to-head comparison of CDK4/6 inhibitors in cell line and animal models of breast cancer reveals important differences, including one drug that exhibits unique, potentially advantageous therapeutic activity.